254 related articles for article (PubMed ID: 29151951)
1. Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer.
Domvri K; Zarogoulidis K; Zogas N; Zarogoulidis P; Petanidis S; Porpodis K; Kioseoglou E; Hohenforst-Schmidt W
J Cancer; 2017; 8(18):3648-3656. PubMed ID: 29151951
[No Abstract] [Full Text] [Related]
2. Sildenafil enhances cisplatin-induced apoptosis in human breast adenocarcinoma cells.
Hassanvand F; Mohammadi T; Ayoubzadeh N; Tavakoli A; Hassanzadeh N; Sanikhani NS; Azimi AI; Mirzaei HR; Khodamoradi M; Goudarzi KA; Pourghadamyari H; Zaimy MA
J Cancer Res Ther; 2020; 16(6):1412-1418. PubMed ID: 33342806
[TBL] [Abstract][Full Text] [Related]
3. Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?
Domvri K; Bougiouklis D; Zarogoulidis P; Porpodis K; Xristoforidis M; Liaka A; Eleutheriadou E; Lampaki S; Lazaridis G; Organtzis J; Kyriazis G; Hohenforst-Schmidt W; Tsirgogianni K; Karavasilis V; Baka S; Darwiche K; Freitag L; Trakada G; Zarogoulidis K
J Cancer; 2015; 6(4):360-6. PubMed ID: 25767606
[TBL] [Abstract][Full Text] [Related]
4. Isorhamnetin flavonoid synergistically enhances the anticancer activity and apoptosis induction by cis-platin and carboplatin in non-small cell lung carcinoma (NSCLC).
Zhang BY; Wang YM; Gong H; Zhao H; Lv XY; Yuan GH; Han SR
Int J Clin Exp Pathol; 2015; 8(1):25-37. PubMed ID: 25755690
[TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis in non-small lung carcinoma cell line (H1299) by combination of anti-asthma drugs with gemcitabine and cisplatin.
Merimsky O; Hirsh L; Dantes A; Land-Bracha A; Suh BS; Amsterdam A
Int J Oncol; 2005 Feb; 26(2):475-82. PubMed ID: 15645133
[TBL] [Abstract][Full Text] [Related]
6. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.
Zhou Y; Pan DS; Shan S; Zhu JZ; Zhang K; Yue XP; Nie LP; Wan J; Lu XP; Zhang W; Ning ZQ
Biomed Pharmacother; 2014 May; 68(4):483-91. PubMed ID: 24721323
[TBL] [Abstract][Full Text] [Related]
7. BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549.
Franks SE; Jones RA; Briah R; Murray P; Moorehead RA
BMC Res Notes; 2016 Mar; 9():134. PubMed ID: 26928578
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase inhibitors as anti-cancer drugs.
Hirsh L; Dantes A; Suh BS; Yoshida Y; Hosokawa K; Tajima K; Kotsuji F; Merimsky O; Amsterdam A
Biochem Pharmacol; 2004 Sep; 68(6):981-8. PubMed ID: 15313391
[TBL] [Abstract][Full Text] [Related]
10. Platinum compounds in the treatment of advanced breast cancer.
MartÃn M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
11. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
12. [Non-cisplatin based chemotherapy in advanced non-small cell lung cancer].
Hosomi Y; Shibuya M
Gan To Kagaku Ryoho; 2007 Apr; 34(4):527-32. PubMed ID: 17431336
[TBL] [Abstract][Full Text] [Related]
13. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
14. Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
Sasaki Y; Shinkai T; Eguchi K; Tamura T; Ohe Y; Ohmori T; Saijo N
Cancer Chemother Pharmacol; 1991; 27(4):263-70. PubMed ID: 1847845
[TBL] [Abstract][Full Text] [Related]
15. Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients.
Hirsch FR; Osterlind K; Jeppesen N; Dombernowsky P; Ingeberg S; Sorensen PG; Kristensen C; Hansen HH
Ann Oncol; 2001 May; 12(5):647-53. PubMed ID: 11432623
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans.
Azar I; Yazdanpanah O; Jang H; Austin A; Kim S; Chi J; Alkassis S; Saha BK; Chopra A; Neu K; Mehdi S; Mamdani H
JAMA Netw Open; 2022 Oct; 5(10):e2237699. PubMed ID: 36264573
[TBL] [Abstract][Full Text] [Related]
17. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin.
Tang CH; Parham C; Shocron E; McMahon G; Patel N
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1389-400. PubMed ID: 20809122
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological approach to the platinum compounds].
Sasaki Y
Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
[TBL] [Abstract][Full Text] [Related]
19. Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin.
Branco H; Oliveira J; Antunes C; Santos LL; Vasconcelos MH; Xavier CPR
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408988
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang R; Chu Z
Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
